Research Unit, University General Hospital of Alicante, and Alicante Institute for Health and Biomedical Research (ISABIAL), Pintor Baeza 12, 03010 Alicante, Spain.
Research Unit, University General Hospital of Alicante, and Alicante Institute for Health and Biomedical Research (ISABIAL), Pintor Baeza 12, 03010 Alicante, Spain.
Pathol Res Pract. 2021 Jul;223:153478. doi: 10.1016/j.prp.2021.153478. Epub 2021 May 13.
Hedgehog (Hh) signaling is a crucial developmental regulatory pathway recognized as a primary oncogenesis driver in various human cancers. However, its role in breast carcinoma (BC) has been underexplored.
We analyzed the expression of several Hh associated genes in a clinical series and breast cancer cell lines. We included 193 BC stratified according to intrinsic immunophenotypes. Gene expression profiling ofBOC, PTCH, SMO, GLI1, GLI2, and GLI3 was performed by qRT-PCR. Results were correlated with clinical-pathological variables and outcome.
We observed expression ofGLI2 in triple-negative/basal-like (TN/BL) and GLI3 in luminal cells. In samples, BOC, GLI1, GLI2, and GLI3 expression correlated significantly with luminal tumors and good prognostic factors. In contrast, PTCH and SMO correlated with TN/BL phenotype and nodal involvement. Patients whose tumors expressed SMO had a poorer outcome, especially those with HER2 phenotype. Positive lymph-node status and high SMO remained independent poor prognostic factors.
Our results support a differential Hh pathway activation in BC phenotypes.SMO levels stratified patients at risk of recurrence and death in HER2 phenotype, and it showed an independent prognostic value. Therefore, SMO could be a potential therapeutic target for a subset of BC patients.
Hedgehog(Hh)信号通路是一个关键的发育调控途径,被认为是多种人类癌症的主要致癌驱动因素。然而,其在乳腺癌(BC)中的作用尚未得到充分探索。
我们分析了临床系列和乳腺癌细胞系中几种与 Hh 相关基因的表达。我们纳入了根据固有免疫表型分层的 193 例 BC。通过 qRT-PCR 对 BOC、PTCH、SMO、GLI1、GLI2 和 GLI3 进行基因表达谱分析。结果与临床病理变量和结局相关。
我们观察到在三阴性/基底样(TN/BL)中表达 GLI2,在 luminal 细胞中表达 GLI3。在样本中,BOC、GLI1、GLI2 和 GLI3 的表达与 luminal 肿瘤和良好的预后因素显著相关。相反,PTCH 和 SMO 与 TN/BL 表型和淋巴结受累相关。肿瘤表达 SMO 的患者预后较差,尤其是 HER2 表型的患者。阳性淋巴结状态和高 SMO 仍然是独立的不良预后因素。
我们的结果支持 BC 表型中 Hh 通路的差异激活。SMO 水平在 HER2 表型中分层了具有复发和死亡风险的患者,并且具有独立的预后价值。因此,SMO 可能是一部分 BC 患者的潜在治疗靶点。